Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NVCT 
Nuvectis Pharma Inc (NVCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: NVCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $18.17
1 Year Target Price $18.17
| 2 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.32% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 155.03M USD | Price to earnings Ratio - | 1Y Target Price 18.17 |
Price to earnings Ratio - | 1Y Target Price 18.17 | ||
Volume (30-day avg) 6 | Beta -0.3 | 52 Weeks Range 4.44 - 11.80 | Updated Date 10/17/2025 |
52 Weeks Range 4.44 - 11.80 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -63.38% | Return on Equity (TTM) -150.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 127730067 | Price to Sales(TTM) - |
Enterprise Value 127730067 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.38 | Shares Outstanding 25456848 | Shares Floating 15445179 |
Shares Outstanding 25456848 | Shares Floating 15445179 | ||
Percent Insiders 39.98 | Percent Institutions 13.85 |
Upturn AI SWOT
Nuvectis Pharma Inc
Company Overview
History and Background
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for serious unmet medical needs in oncology. It was incorporated in 2020.
Core Business Areas
- Drug Development: Development of NUV-868, an oral small molecule HSF1 activator for cancer treatment.
Leadership and Structure
The company's leadership includes Ron Bentsur (CEO) and the organizational structure consists of research, development, and management teams.
Top Products and Market Share
Key Offerings
- NUV-868: An oral small molecule HSF1 activator in Phase 1 clinical trial for cancer. Market share is currently 0% as it is in development stage. Competitors include companies with similar HSF1 targeting or cancer treatments.
Market Dynamics
Industry Overview
The oncology market is characterized by high growth, increasing incidence of cancer, and continuous innovation in treatment modalities.
Positioning
Nuvectis Pharma aims to address unmet needs in cancer treatment with precision medicines, particularly through HSF1 activation. Their competitive advantage lies in the novel mechanism of action of NUV-868.
Total Addressable Market (TAM)
The global oncology market is projected to reach several hundred billion USD. Nuvectis Pharma is positioned to capture a share of this market by addressing specific cancer types where HSF1 activation may be beneficial.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (HSF1 activation)
- Precision medicine approach
- Experienced management team
Weaknesses
- Early stage clinical development (high risk)
- Limited financial resources
- Reliance on single drug candidate
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through in-licensing or acquisitions
Threats
- Clinical trial failures
- Competition from established cancer therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- MRTX
- ARVN
- GILD
Competitive Landscape
Nuvectis Pharma competes with other oncology companies in the development of new cancer therapies. Its novel HSF1 activation mechanism differentiates it from companies pursuing traditional approaches.
Growth Trajectory and Initiatives
Historical Growth: Since its incorporation in 2020, growth has been focused on advancing NUV-868 through preclinical and early clinical stages.
Future Projections: Future growth depends on the success of NUV-868 in clinical trials and potential partnerships. Analyst estimates are not widely available due to the early stage nature of the company.
Recent Initiatives: Recent initiatives include initiating and continuing Phase 1 clinical trial for NUV-868.
Summary
Nuvectis Pharma is a high-risk, high-reward biopharmaceutical company in the early stages of clinical development. The company's strength lies in its novel mechanism of action, but it faces challenges related to funding, regulatory approval, and competition. Success hinges on positive clinical trial results for NUV-868 and securing partnerships to support further development. They need to carefully monitor its spending and progress in clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- ClinicalTrials.gov
- Market Research Reports on Oncology
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are based on general oncology markets and not specific to NUV-868's potential indications.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvectis Pharma Inc
Exchange NASDAQ | Headquaters Fort Lee, NJ, United States | ||
IPO Launch date 2022-02-04 | Co-Founder, Chairman, CEO & President Mr. Ron Bentsur M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.nuvectis.com |
Full time employees 13 | Website https://www.nuvectis.com | ||
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.